AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|AAPL299.77+1.76 (+0.59%) ▲|ABBV230.63+14.14 (+6.53%) ▲|ABT87.83-0.59 (-0.66%) ▼|ACN121.53-6.45 (-5.04%) ▼|ADBE193.54-1.63 (-0.83%) ▼|AMAT627.06+9.95 (+1.61%) ▲|AMD546.40+9.03 (+1.68%) ▲|AMGN342.18+4.58 (+1.36%) ▲|AMT177.24+1.19 (+0.68%) ▲|AMZN233.57-10.82 (-4.43%) ▼|AVGO394.92-16.43 (-3.99%) ▼|AXP337.15-0.86 (-0.25%) ▼|BA221.59-1.13 (-0.51%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG165.27-6.51 (-3.79%) ▼|BLK1,050.06-0.03 (0.00%) ▼|BMY54.35+0.35 (+0.64%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B490.10+0.64 (+0.13%) ▲|C145.74+2.68 (+1.87%) ▲|CAT1,016.41+30.59 (+3.10%) ▲|CL90.52+1.04 (+1.16%) ▲|CMCSA22.41-0.03 (-0.11%) ▼|COF199.29-2.24 (-1.11%) ▼|COP109.01+1.27 (+1.18%) ▲|COST950.35-1.10 (-0.12%) ▼|CRM149.09-2.69 (-1.77%) ▼|CSCO121.05+1.51 (+1.26%) ▲|CVS102.59+4.27 (+4.34%) ▲|CVX173.80+0.17 (+0.10%) ▲|DE603.46+14.22 (+2.41%) ▲|DHR175.83-1.34 (-0.76%) ▼|DIS102.88-1.01 (-0.97%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.68+0.02 (+0.01%) ▲|FDX329.82+4.84 (+1.49%) ▲|GD345.22-4.79 (-1.37%) ▼|GE357.640.00 (0.00%) ▼|GEV1,114.95+5.22 (+0.47%) ▲|GILD123.82+0.06 (+0.05%) ▲|GM82.58+3.29 (+4.15%) ▲|GOOG342.22-25.24 (-6.87%) ▼|GOOGL342.77-25.26 (-6.86%) ▼|GS1,094.90-1.66 (-0.15%) ▼|HD329.78-4.50 (-1.35%) ▼|HON231.08+2.07 (+0.90%) ▲|IBM246.19-2.92 (-1.17%) ▼|INTC140.02+6.03 (+4.50%) ▲|INTU258.80-8.20 (-3.07%) ▼|ISRG401.85-4.94 (-1.21%) ▼|JNJ230.89+2.50 (+1.09%) ▲|JPM330.36+5.14 (+1.58%) ▲|KO79.54+0.15 (+0.18%) ▲|LIN512.40+0.25 (+0.05%) ▲|LLY1,098.30-0.27 (-0.02%) ▼|LMT495.22-15.73 (-3.08%) ▼|LOW216.04-6.16 (-2.77%) ▼|LRCX394.19+5.15 (+1.32%) ▲|MA487.65-2.14 (-0.44%) ▼|MCD274.12-4.49 (-1.61%) ▼|MDLZ60.06-0.06 (-0.10%) ▼|MDT78.90-0.44 (-0.55%) ▼|META561.37-15.85 (-2.75%) ▼|MMM162.94+2.34 (+1.45%) ▲|MO69.98+0.86 (+1.24%) ▲|MRK113.73-0.15 (-0.13%) ▼|MS226.88+3.71 (+1.66%) ▲|MSFT371.46-7.94 (-2.09%) ▼|MU1,191.02+57.03 (+5.03%) ▲|NEE87.21+0.46 (+0.53%) ▲|NFLX74.12-3.26 (-4.22%) ▼|NKE43.52-1.68 (-3.72%) ▼|NOW93.18-1.86 (-1.96%) ▼|NVDA209.31-1.38 (-0.66%) ▼|ORCL178.82-5.47 (-2.97%) ▼|PEP141.71-0.31 (-0.22%) ▼|PFE25.11-0.10 (-0.38%) ▼|PG150.08-0.31 (-0.20%) ▼|PLTR122.33-6.14 (-4.78%) ▼|PM175.39-3.01 (-1.69%) ▼|QCOM228.57+2.46 (+1.09%) ▲|RTX181.93-3.67 (-1.98%) ▼|SBUX100.87+0.22 (+0.21%) ▲|SCHW91.86+0.16 (+0.17%) ▲|SO93.80+0.71 (+0.76%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.37+0.36 (+1.64%) ▲|TMO459.70-4.92 (-1.06%) ▼|TMUS180.80-0.87 (-0.48%) ▼|TSLA408.50+8.01 (+2.00%) ▲|TXN332.07+9.21 (+2.85%) ▲|UBER71.77+0.13 (+0.17%) ▲|UNH405.93+4.97 (+1.24%) ▲|UNP261.35+4.47 (+1.74%) ▲|UPS107.99+3.13 (+2.98%) ▲|USB58.85+0.71 (+1.21%) ▲|V330.32+3.08 (+0.94%) ▲|VZ45.65+0.28 (+0.62%) ▲|WFC83.42+1.22 (+1.48%) ▲|WMT117.70+0.52 (+0.44%) ▲|XOM137.76-0.05 (-0.04%) ▼|
22.8 C
New York
Monday, June 22, 2026

Tag: clinical trial

newssourceFORcompanyinformationcontent1marketreleases

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO,...

SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud — Contact BFA Law (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud investigation.

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025.

HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight

The future of the HER2-low cancer treatment market is poised for significant transformation, driven by the approval of ENHERTU and the advancement of other...

Delta-like Ligand 3 Targeted Therapies Market is Predicted to Heat Up During the Forecast Period (2025-2034) Across 7MM Owing to a Robust Pipeline |...

The delta-like ligand 3 targeted therapies market is witnessing significant growth, driven by the rising incidence of small cell lung cancer (SCLC) and neuroendocrine...

Memo Therapeutics AG to Present Interim Phase II Results of Potravitug for the Treatment of BKV Infection in Kidney Transplant Recipients in a Late...

PRESS RELEASE

Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations

SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the...

The Department of Health – Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi

On the sidelines of a high-level US visit focused on healthcare innovation ABU DHABI, UAE, June 19, 2025 /PRNewswire/ -- The Department of Health – Abu...

Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans

HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased...

Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has...

LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma

Expanding track record by signing contracts with various global companies across Asia and EuropeSEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers